Timing of Maximum Tumor Shrinkage May Predict mRCC Pt Survival

Share this content:
Hyponatremia Lengthens Cancer Patient Hospital Stay
Hyponatremia Lengthens Cancer Patient Hospital Stay

NEW ORLEANS—The timing of maximum tumor shrinkage in patients with metastatic renal cell carcinoma (mRCC) may be useful as a biomarker for predicting overall survival, Japanese researchers reported at the 2015 American Urological Association annual meeting.

Takafumi Yagisawa, MD, and colleagues at Tokyo Women's Medical University, based this conclusion on a study of 199 mRCC patients receiving first-line systemic therapy with targeted agents. The study showed that the 81 patients who had maximum tumor shrinkage within 3 months—as measured by computed tomography (CT)—had significantly longer overall survival than the 48 patients who had maximum shrinkage after 3 months (22.8 vs. 14.3 months).

The agents used for first-line therapy included sunitinib (71 patients), sorafenib (47 patients), pazopanib (4 patients), and temsirolimus (7 patients).

You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters